Form 4 for XFOR X4 Pharmaceuticals, Inc

Accepted 2025-01-27 00:00:00 ET · period of report 2025-01-23 · accession 0001628280-25-002705 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2025-01-27	2025-01-23	XFOR	Arbet-Engels Christophe	Chief Medical Off	A - Grant	$0.00	+25.8K	25.8K	New	$0
	2025-01-27	2025-01-24	XFOR	Arbet-Engels Christophe	Chief Medical Off	S - Sale	$0.45	-11.6K	14.2K	-45%	-$5,231

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-01-23	A	A	25,831	$0.00	25,831	D	—	—	(F1) Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurred upon the acceptance by the European Medicines Agency of the Issuer's Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome.
2	Common	Common Stock	2025-01-24	S	D	11,624	$0.45	14,207	D	—	—	(F2) These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.4478 to $0.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.